Evidence map›Paper›PMID 32760069›Full record

ArticlePloS one2020

Screening anti-infectious molecules against Mycobacterium ulcerans: A step towards decontaminating environmental specimens.

Nassim Hammoudi, Romain Verdot, Jean Delorme, Amar Bouam, Michel Drancourt

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Nassim HammoudiIHU Méditerranée Infection, Marseille, France.
Romain VerdotIHU Méditerranée Infection, Marseille, France.
Jean DelormeAssistance Publique - Hôpitaux de Marseille, Pharmacie Centrale, Marseille, France.
Amar BouamAix-Marseille University, IRD, MEPHI, IHU Méditerranée Infection, Marseille, France.
Michel DrancourtIHU Méditerranée Infection, Marseille, France.ORCID 0000-0003-0768-1139
Aix-Marseille Université · FRAssistance Publique Hôpitaux de Marseille · FRMéditerranée Infection Foundation · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycobacterium ulcerans, a non-tuberculous mycobacterium responsible for Buruli ulcer, resides in poorly defined environmental niches in the vicinity of stagnant water. Very few isolates have been confirmed. With a view to culturing M. ulcerans from such contaminated environmental specimens, we tested the in vitro susceptibility of the M. ulcerans CU001 strain co-cultivated with XTC cells to anti-infectious molecules registered in the French pharmacopoeia. We used a standardised concentration to identify molecules that were inactive against M. ulcerans and which could be incorporated into a decontaminating solution. Of 116 tested molecules, 64 (55.1%) molecules were ineffective against M. ulcerans CU001. These included 34 (29.3%) antibiotics, 14 (12%) antivirals, eight (6.8%) antiparasitics, and eight (6.8%) antifungals. This left 52 molecules which were active against M. ulcerans CU001. Three of the inactive antimicrobial molecules (oxytetracycline, polymyxin E and voriconazole) were then selected to prepare a decontamination solution which was shown to respect M. ulcerans CU001 viability. These three antimicrobials could be incorporated into a decontamination solution to potentially isolate and culture M. ulcerans from environmental samples.

Indexed as

Anti-Infective AgentsBuruli UlcerColistinHumansMass ScreeningMicrobial Sensitivity TestsMycobacteriumMycobacterium ulceransOxytetracyclineVoriconazoleAnti-Infective AgentsColistinOxytetracyclineVoriconazole

Identifiers

PMID32760069
PMCPMC7410233
OpenAlexW3048251433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.